Megan Sutton, DNP, ACNP-BC, is an experienced Clinician and accomplished Strategic Pharmaceutical Leader with an extensive career spanning over two decades. Beginning as a dedicated Nurse Practitioner, she gained valuable experience in patient care for over a decade before transitioning to the pharmaceutical industry. Throughout her career, Megan has been involved in the successful launch of three innovative therapies, including ENTRESTO® for Heart Failure, ANDEXXA® for Factor Xa Inhibitor reversal, and CAMZYOS® for Hypertrophic Cardiomyopathy, significantly impacting patient care on a global scale. Her roles in the pharmaceutical landscape have been diverse, encompassing Medical Affairs, Real-World Evidence (RWE), and Clinical Development. Presently, Megan holds the position of Senior Medical Director and Clinical Lead for a pioneering Gene Therapy trial focused on a rare genetic cardiomyopathy, contributing to innovative research aimed at improving patient outcomes.
Conor Wyand currently is the Senior Director of Life Science Solutions at Truveta where he leads a team responsible for engaging with potential new Life Science customers. Prior to joining Truveta in 2021, Conor spent six years in various leadership positions at Optum Life Sciences, working with Pharmaceutical and Medical Device manufacturers across the value chain to generate Real World Evidence for therapeutics and devices. Conor graduated from Brown University with a Bachelor's Degree in Applied Mathematics and Economics.
